Astellas Pharma

ACT Core

The company scores 4 for the quality of their transition plan and 0 for their contribution to the transition, resulting in a total score of C - Inconsequential planning. This reflects that the company has set valid targets for its most material emissions scopes. It has a transition plan with oversight to the highest governance body, and is reporting emissions under a recognised methodology. However, there is no evidence that the company is mobilizing low-carbon investments through capital expenditure (CapEx) or R&D. In addition, the company’s Scope 1 and 2 and Scope 3 emissions data for the period 2019–2024 are either not reported consistently for at least four years, or the emissions trajectory is significantly misaligned with the reductions required under the relevant 1.5 °C sectoral pathway. Disclosing information on low-carbon investments and providing consistent emissions time series that demonstrate significant emissions reductions would move the company to a higher classification. The graphs below indicate the company’s performance compared to the overall distribution of results for selected aspects. However, the total score refers to a much wider set of indicators and also consider such as the company’s emission disclosure, transition plan, aspects of governance and support for climate policy.